Reliable Brokers
Online Investing
Alerts & Analysis
Easy Trading

PainReform (NASDAQ: PRFX) up 26% again - no, we’d steer clear of this one

There’s just something about the stock issuance last week that turns us off

Update : 20 Jul 2023, 06:20 PM

PainReform (NASDAQ: PRFX) stock is back up 26% on Thursday. PRFN stock also fell 8% yesterday - so we've certainly got the volatility that is the traders' friend. But we have to admit that this isn't a stock we'd like to play with. There's nothing specific we can say - we've no insider information or anything. But we'd just be uncomfortable given those events of last week.

For here's what happened. There was a massive leap in the PRFX stock price: “PainReform (NASDAQ: PRFX) stock was up 307% yesterday. PRFX stock is also down 18% since then. It's always possible for a pharma stock to justifiably have this sort of price movement. Something like an unexpected FDA approval of a drug or treatment can cause something like this. Even just good results from a trial which might lead to such approval can cause this. On the other hand, exactly because such price movements can happen at times certain actors try to cause such price moves - because they're believable, at least for a while. When such price moves happen because someone is deliberately trying to cause them we refer to it as a pump and dump.”

No, we still don't know what did cause that leap in the stock price there.

PainReform stock price from NASDAQ

We don't know what caused that surge but we do know what happened next: “PainReform (NASDAQ:PRFX) has entered into a definitive agreement for the purchase and sale of 301,230 of the Co.'s ordinary shares, at a purchase price of $9/ordinary share, in a registered direct offering.”

Now it's possible to read this in one of two ways. One is that management is very canny. Some price rise occurs, they're smart enough to use it to raise necessary capital for the company. But that does also mean that any future significant price rise might well be met with a money raise - making the speculation much less interesting. 

But there's also that entirely untrue thought that perhaps the price rise happened in order to sell the stock. That isn't true, we know that, but it's always something that will be at the back of the mind. 

So, well, no. There are enough small cap pharma companies out there that it's possible to go play elsewhere. So that's what we'll do.

Top Brokers